Form 8-K - Current report:
SEC Accession No. 0001140361-24-042968
Filing Date
2024-10-07
Accepted
2024-10-07 16:13:57
Documents
22
Period of Report
2024-10-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20036564_8k.htm   iXBRL 8-K 42151
2 EXHIBIT 3.1 ef20036564_ex3-1.htm EX-3.1 68183
3 EXHIBIT 3.2 ef20036564_ex3-2.htm EX-3.2 522098
4 EXHIBIT 3.3 ef20036564_ex3-3.htm EX-3.3 28547
5 EXHIBIT 3.4 ef20036564_ex3-4.htm EX-3.4 130887
6 EXHIBIT 4.1 ef20036564_ex4-1.htm EX-4.1 13384
10 image00001.jpg GRAPHIC 294394
11 image00002.jpg GRAPHIC 1946
12 image00003.jpg GRAPHIC 5731
13 image00004.jpg GRAPHIC 61069
  Complete submission text file 0001140361-24-042968.txt   1572525

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA acst-20241001.xsd EX-101.SCH 3976
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE acst-20241001_lab.xml EX-101.LAB 22691
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acst-20241001_pre.xml EX-101.PRE 16548
24 EXTRACTED XBRL INSTANCE DOCUMENT ef20036564_8k_htm.xml XML 4387
Mailing Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540
Business Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540 609-322-1602
Acasti Pharma Inc. (Filer) CIK: 0001444192 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-35776 | Film No.: 241358005
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)